公司資料
Arcus Biosciences 股價、新聞與催化劑
- 股票代碼:
- RCUS
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
29.56 USD (+0.27%)
收盤價
最後更新: 2026年8月17日
3.08B USD
市值
股價為何變動
As of Aug 17, 2026, RCUS closed up 0.27% at $29.56. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Arcus Biosciences is an oncology company focused on immuno-oncology combinations and targeted cancer therapies. Its platform is built to create differentiated regimens in solid tumors.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Arcus sits in clinical-stage oncology biotechnology.
商業模式特徵
The company depends on clinical data, partnership economics, and the ability to translate combination science into durable cancer programs.
生技產業定位
Arcus is a catalyst-sensitive oncology name whose stock moves on readouts, combination strategy, and partner progress.
未來催化劑
- Arcus's catalysts are domvanalimab/zimberelimab combinations and casdatifan in oncology, where the next readouts determine whether the platform can keep its premium. The company remains a key immuno-oncology and HIF-2α story.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。